Avid Bioservices, Inc. (Nasdaq: CDMO) reported a net loss of approximately $0.3 million for the fourth quarter of fiscal 2023, which fell short of the consensus estimate of breakeven.

Looking ahead to fiscal 2024, the company anticipates revenue in the range of $145 million to $165 million, also falling short of the consensus estimate of $181.27 million for the period.

$CDMO was trading at $12.42 in after-hours, down $3.15 (20.23%).

Snap-on Incorporated (NYSE: SNA), a leading manufacturer and marketer of high-quality tools, equipment, and diagnostic solutions, was reiterated with a Buy rating by Tigress Financial, who raised the price target from $302 to $328. 

Despite $SNA closing at $301.10 on Wednesday, this adjusted price target suggests a potential upside of $26.90 or 8.93%, as per the financial services firm's view.

Constellation Brands, Inc.? (NYSE: STZ), a prominent producer and marketer of beer, wine, and spirits, was maintained with a Buy rating by Citigroup, with the price target raised from $265 to $280. 

With $STZ closing at $272.88 on Wednesday, the revised price target implies a potential upside of $7.12 or 2.61%, as per the investment firm's assessment.

WESCO International, Inc. (NYSE: WCC), a leading provider of electrical, industrial, and communications products, was maintained with a Buy rating by Loop Capital, who raised the price target from $170 to $210. 

Based on Wednesday's closing price of $173.39, the adjusted price target indicates a potential upside of $36.61 or 21.12% for $WCC, according to the brokerage and advisory firm's analysis.

Tyler Technologies, Inc. (NYSE: TYL), a software company specializing in providing integrated information management solutions and services for the public sector, was initiated with an Overweight rating and a price target of $472 by JP Morgan. 

With $TYL closing at $392.19 on Wednesday, the newly established price target suggests a potential upside of $79.81 or 20.35%, according to the investment firm's viewpoint.

Avantor, Inc. (NYSE: AVTR), a global provider of products, services, and solutions for the life sciences and advanced technologies industries, was initiated with an Outperform rating and a price target of $27 by RBC Capital Markets. 

Despite closing at $19.71 on Wednesday, the initiated price target indicates a potential upside of $7.29 or 36.99% for $AVTR, based on the investment firm's assessment.

Surmodics, Inc. (Nasdaq: SRDX), a medical device company focused on developing and commercializing innovative products to improve patient outcomes, was maintained with an Outperform rating by Barrington Research, who raised the price target from $60 to $69. 

Based on Wednesday's closing price of $30.10, the adjusted price target implies a potential upside of $38.90 or 129.23% for $SRDX, according to Barrington Research's analysis.

Please bear in mind that the potential upsides indicated for these companies are derived from the assessments and recommendations of brokerage firms, investment firms, or analysts, reflecting their perspective on the future performance of each respective company. It is advisable for investors to conduct their own research and take into account additional factors before making any investment decisions

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)